Jeffrey M. Axten

3.1k total citations · 2 hit papers
29 papers, 1.9k citations indexed

About

Jeffrey M. Axten is a scholar working on Molecular Biology, Organic Chemistry and Cell Biology. According to data from OpenAlex, Jeffrey M. Axten has authored 29 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Organic Chemistry and 9 papers in Cell Biology. Recurrent topics in Jeffrey M. Axten's work include Endoplasmic Reticulum Stress and Disease (8 papers), Autophagy in Disease and Therapy (5 papers) and Chemical Synthesis and Analysis (4 papers). Jeffrey M. Axten is often cited by papers focused on Endoplasmic Reticulum Stress and Disease (8 papers), Autophagy in Disease and Therapy (5 papers) and Chemical Synthesis and Analysis (4 papers). Jeffrey M. Axten collaborates with scholars based in United States, United Kingdom and Netherlands. Jeffrey M. Axten's co-authors include Jeffrey D. Winkler, Claudio Hetz, John B. Patterson, Colin Molloy, David A. Barrett, Julie A. Moreno, Peter M. Fischer, Nicholas Verity, Mark Halliday and Helois Radford and has published in prestigious journals such as Journal of the American Chemical Society, Cancer Research and Biochemical Journal.

In The Last Decade

Jeffrey M. Axten

29 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice

2013 453 citations Jeffrey M. Axten et al. profile →
Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity

2013 364 citations Charity Atkins, Qi Liu et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey M. Axten United States	16	998	933	512	322	157	29	1.9k
Allan S. Wagman United States	17	167 0.2×	1.4k 1.5×	145 0.3×	447 1.4×	138 0.9×	28	2.2k
W. Christian Wigley United States	22	445 0.4×	1.5k 1.6×	151 0.3×	77 0.2×	81 0.5×	35	2.0k
David A. Priestman United Kingdom	26	492 0.5×	1.1k 1.2×	255 0.5×	248 0.8×	188 1.2×	58	2.2k
Daniel Canals United States	27	438 0.4×	1.6k 1.7×	191 0.4×	169 0.5×	94 0.6×	48	2.0k
Carlos A. Gartner United States	13	441 0.4×	1.3k 1.4×	294 0.6×	165 0.5×	58 0.4×	25	1.7k
Jean‐Pierre Jaffrézou France	29	388 0.4×	2.1k 2.3×	154 0.3×	119 0.4×	104 0.7×	45	2.7k
Tyzoon Nomanbhoy United States	25	447 0.4×	2.3k 2.5×	72 0.1×	449 1.4×	155 1.0×	47	3.3k
Richard D. Bagshaw Canada	23	842 0.8×	1.2k 1.3×	186 0.4×	70 0.2×	50 0.3×	32	2.1k
Mai Uesugi Japan	12	273 0.3×	1.0k 1.1×	148 0.3×	116 0.4×	44 0.3×	17	1.5k
Anu R. Sawkar United States	9	628 0.6×	844 0.9×	276 0.5×	562 1.7×	30 0.2×	10	1.5k

Countries citing papers authored by Jeffrey M. Axten

Since Specialization

Citations

This map shows the geographic impact of Jeffrey M. Axten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey M. Axten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey M. Axten more than expected).

Fields of papers citing papers by Jeffrey M. Axten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey M. Axten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey M. Axten. The network helps show where Jeffrey M. Axten may publish in the future.

Co-authorship network of co-authors of Jeffrey M. Axten

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey M. Axten. A scholar is included among the top collaborators of Jeffrey M. Axten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey M. Axten. Jeffrey M. Axten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reihill, James, Melisa W-Y. Ho, Jeffrey M. Axten, et al.. (2022). A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease. Cell chemical biology. 29(6). 947–957.e8. 18 indexed citations

Hetz, Claudio, Jeffrey M. Axten, & John B. Patterson. (2019). Pharmacological targeting of the unfolded protein response for disease intervention. Nature Chemical Biology. 15(8). 764–775. 196 indexed citations

Mercado, Gabriela, Valentina Castillo, Paulina Soto, et al.. (2018). Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease. Neurobiology of Disease. 112. 136–148. 128 indexed citations

Ornaghi, Francesca, Elena Restelli, Alessandro Corbelli, et al.. (2018). PERK inhibition delays neurodegeneration and improves motor function in a mouse model of Marinesco-Sjögren syndrome. Human Molecular Genetics. 27(14). 2477–2489. 41 indexed citations

Laping, Nicholas J., Michael P. DeMartino, Joshua E. Cottom, et al.. (2017). TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis. Blood Advances. 1(26). 2553–2562. 2 indexed citations

Axten, Jeffrey M.. (2016). Protein kinase R(PKR)–like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015). Expert Opinion on Therapeutic Patents. 27(1). 37–48. 24 indexed citations

Atkins, Charity, Qi Liu, Elisabeth A. Minthorn, et al.. (2013). Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity. Cancer Research. 73(6). 1993–2002. 364 indexed citations breakdown →

Liu, Huaping, Metin Kurtoğlu, Haibin Xi, et al.. (2013). Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells. Cancer Chemotherapy and Pharmacology. 72(1). 251–262. 19 indexed citations

Axten, Jeffrey M., Jesús R. Medina, Charles W. Blackledge, et al.. (2012). Acylprolinamides: A new class of peptide deformylase inhibitors with in vivo antibacterial activity. Bioorganic & Medicinal Chemistry Letters. 22(12). 4028–4032. 5 indexed citations

10.

Duquenne, Céline, Timothy F. Gallagher, & Jeffrey M. Axten. (2010). A novel method for the 1,2-carbonyl transposition of pleuromutilins. Tetrahedron Letters. 51(15). 1937–1938. 4 indexed citations

11.

Medina, Jesús R., Seth W. Grant, Jeffrey M. Axten, et al.. (2010). Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorganic & Medicinal Chemistry Letters. 20(8). 2552–2555. 13 indexed citations

12.

DeYoung, M. Phillip, et al.. (2010). Abstract LB-42: PDK1 knockdown selectively inhibits growth of cancer cells harboring activating mutations involved in MAPK signaling. Cancer Research. 70(8_Supplement). LB–42. 2 indexed citations

13.

Najafov, Ayaz, Eeva Sommer, Jeffrey M. Axten, M. Phillip DeYoung, & Dario R. Alessi. (2010). Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochemical Journal. 433(2). 357–369. 108 indexed citations

14.

Medina, Jesús R., Charles W. Blackledge, Karl F. Erhard, Jeffrey M. Axten, & William H. Miller. (2008). Benzyl 2-Cyano-3,3-Dimethyl-1-pyrrolidinecarboxylate, a Versatile Intermediate for the Synthesis of 3,3-Dimethylproline Derivatives. The Journal of Organic Chemistry. 73(10). 3946–3949. 6 indexed citations

15.

Winkler, Jeffrey D. & Jeffrey M. Axten. (1998). The First Total Syntheses of Ircinol A, Ircinal A, and Manzamines A and D. Journal of the American Chemical Society. 120(25). 6425–6426. 127 indexed citations

16.

Winkler, Jeffrey D., Jeffrey M. Axten, Young‐Shin Kwak, et al.. (1998). Stereoselective synthesis of the tetracyclic core of manzamine via the vinylogous amide photocycloaddition cascade. Tetrahedron. 54(25). 7045–7056. 21 indexed citations

17.

Axten, Jeffrey M., et al.. (1998). A Stereoselective Synthesis of dl-threo-Methylphenidate: Preparation and Biological Evaluation of Novel Analogues. The Journal of Organic Chemistry. 63(26). 9628–9629. 40 indexed citations

18.

Winkler, Jeffrey D., et al.. (1996). Two highly efficient syntheses of scalemic azocines. Tetrahedron Letters. 37(25). 4317–4318. 28 indexed citations

19.

Axten, Jeffrey M., et al.. (1994). An ab initio molecular orbital study of the grignard reagents CH3MgCl and [CH3MgCl]2: The Schlenk equilibrium. Structural Chemistry. 5(2). 99–108. 15 indexed citations

20.

McDonnell, Mark E., et al.. (1992). Synthesis and Characterization of Novel Ferrocenyl-Substituted Pyrroles. Synthetic Communications. 22(22). 3271–3275. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact